Funder
This study was supported by a Grant-in-Aid for Clinical Research from University of Miyazaki Hospital.
This study was supported by Grant-in-Aid from the Ministry of Health, Labor and Welfare of Japan.
Publisher
Springer Science and Business Media LLC
Reference14 articles.
1. Thiele J, Kvasnicka HM, Orazi A, Gianeli U, Barbui T, Barosi G, et al. Myeloproliferative neoplasms. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO classification of tumors of haematopoietic and lymphoid tissues. IARC Press: Lyon; 2017. pp. 39–53.
2. Cerquozzi S, Tefferi A. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer J. 2015;5:e366.
3. Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29:761–70.
4. Juan-Carlos H-B, Arturo P, Montse G, Concepción B, Francisca F-M, José-María R, et al. The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis. Haematologica. 2014;99:e55–7.
5. Tefferi A, Saeed L, Hanson CA, Ketterling RP, Pardanani A, Gangat N. Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis. Leukemia. 2017;31:2851–2.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献